APP and amyloidosis: Emerging evidence suggests that partial reduction of BACE1, which is induced by BACE1+/− gene deletion [21], [22], siRNA targeting BACE1 [18] and immunization with BACE1 ectodomain [19], can diminish brain Aβ levels and amyloid-related pathologies and improve synaptic and cognitive dysfunctions in different APP transgenic mice.